Related Experiment Video
Updated: Aug 21, 2026
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?
1Urological Diseases Research Center, Children's Hospital Boston, Harvard Medical School, Enders Research Laboratories, Suite 1161, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. michael.freeman@childrens.harvard.edu
Abstract:
In this issue of Cancer Cell, Mellinghoff et al. (2004) demonstrate that a small molecule inhibitor of the EGF receptor (EGFR) and the HER2/ErbB2/c-Neu kinase blocks signaling to the androgen receptor by a mechanism that involves HER2/HER3 heterodimerization. Surprisingly, the EGFR is peripheral to this signaling mechanism. These results have implications for the design of targeted therapy for hormone-refractory prostate cancer.
Insights
A novel small molecule inhibitor targeting the epidermal growth factor receptor (EGFR) and HER2/ErbB2/c-Neu kinase blocks androgen receptor signaling. This occurs via HER2/HER3 heterodimerization, impacting targeted therapy for prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Prostate cancer remains a significant health concern, with hormone-refractory prostate cancer (HRPC) presenting a therapeutic challenge.
- Targeted therapies aim to inhibit specific molecular pathways driving cancer growth.
- The epidermal growth factor receptor (EGFR) and HER2/ErbB2/c-Neu pathways are implicated in various cancers.
Purpose of the Study:
- To investigate the mechanism by which a small molecule inhibitor affects androgen receptor (AR) signaling in the context of prostate cancer.
- To elucidate the role of EGFR and HER2/ErbB2/c-Neu kinases in AR signaling.
- To explore the therapeutic potential of this inhibitor for hormone-refractory prostate cancer.
Main Methods:
- Utilized a small molecule inhibitor targeting EGFR and HER2/ErbB2/c-Neu kinases.
- Investigated the impact of the inhibitor on androgen receptor signaling.
- Examined the role of HER2/HER3 heterodimerization in the observed signaling blockade.
Main Results:
- The small molecule inhibitor effectively blocked signaling to the androgen receptor.
- HER2/HER3 heterodimerization was identified as a key mechanism in this signaling blockade.
- Epidermal growth factor receptor (EGFR) was found to be peripheral to this specific signaling pathway.
Conclusions:
- The findings reveal a novel mechanism for inhibiting androgen receptor signaling relevant to prostate cancer.
- HER2/HER3 heterodimerization is a critical mediator in the inhibitor's action.
- These results provide a basis for designing targeted therapies for hormone-refractory prostate cancer, potentially involving inhibitors of EGFR and HER2/ErbB2/c-Neu kinases.
